Showing 1 posts of 1 posts found.
A payer is suing Gilead over the price of its hep-c drug Sovaldi in the US after spending $2.4 million …
NHS England approves delayed-release treatment for rare kidney disease
Product value to pathway impact: What the CVD Modern Service Framework means for pharma
Functional lung imaging offers new possibilities for respiratory care
Five Facts about cardiovascular disease
Data integrity: the keystone for AI adoption, patient safety and organisational reputation